Target intelligence / Profile preview

MicroRNA 6891 (MIR6891)

Target
MIR6891
Molecular classification
MicroRNA, non-coding RNA, mirtron
01

Overview

MicroRNA 6891 (MIR6891) is a short (~22 nucleotide), non-coding RNA transcript derived from intron 4 of the HLA-B gene, classifying it as a mirtron microRNA[1][2][3]. It is processed by the Dicer enzyme into mature miR-6891-5p and miR-6891-3p strands. As with other microRNAs, it participates in post-transcriptional gene silencing by binding target mRNA transcripts—most notably, it regulates IGHA1 and IGHA2, influencing immunoglobulin A (IgA) expression in B lymphocytes[1]. MIR6891 may have a role in immune function and selective IgA deficiency, a condition characterized by low or absent IgA. No drugs currently target MIR6891, it is not an established therapeutic receptor or enzyme, and there is no known direct link to major diseases beyond immunological processes[1][2][3].

Other names
hsa-mir-6891microRNA mir-6891MIR6891-5pMIR6891-3p
02

Mechanism of action

RNA-induced silencing complex (RISC) loading for mRNA degradation or translational repression Post-transcriptional inhibition of IGHA1 and IGHA2 via non-canonical binding to 3’UTR

03

Biological functions

Post-transcriptional regulation of gene expressionRegulation of immunoglobulin heavy chain alpha 1 and 2 (IGHA1, IGHA2) transcriptsImmune system modulation
04

Disease associations

Potential involvement in selective IgA deficiencyOther immunological processes; no direct association with cancer, neurodegeneration, inflammation, or infection established
05

Biomarkers

Expression levels may serve as experimental biomarkers for selective IgA deficiencyNo established clinical or companion diagnostic biomarkers

Beyond the preview

Go deeper on MicroRNA 6891 (MIR6891).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 6891 (MIR6891).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call